Related Experiment Video
Updated: Aug 11, 2026

08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Hattrick against Lymphoma with Trispecific CAR T Cells
Maximilian Merz1, Efrat Luttwak2
1Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Blood Cancer Discovery
|August 10, 2026
Abstract
None:
Vasu and colleagues report one of the first clinical evaluations of rapidly manufactured trispecific chimeric antigen receptor T cells targeting CD19, CD20, and CD22. The lymphoma efficacy signal and favorable observed safety profile support further investigation, whereas the correlative analyses suggest that baseline T-cell fitness and early post-infusion functional states may remain important determinants of outcome. See related article by Vasu et al., p. XX .

